Skip to main content

Table 1 Association of risk factors of HLA-SE and smoking with multiplex positivity in anti-CCP-2-negative RA patients

From: An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting

 

Shared epitope

   
 

No, n (%)

Yes, n (%)

OR (95 % CI)

P value

CCP-2−

140 (57)

107 (43)

Reference

 

CCP-2+

54 (21)

199 (79)

4.82 (3.26-7.14)

<0.001

CCP-2−Multiplex−

93 (55)

78 (46)

Reference

 

CCP-2−Multiplex+

47 (60)

29 (39)

0.74 (0.42-1.28)

0.28

CCP-2−Multiplex+

47 (62)

29 (38)

Reference

 

CCP-2+Multiplex+

51 (21)

192 (79)

6.10 (3.50-10.64)

<0.001

 

Ever smoker

   
 

No, n (%)

Yes, n (%)

OR (95 % CI)

P value

CCP-2−

274 (78)

78 (22)

Reference

 

CCP-2+

301 (69)

138 (31)

1.61 (1.17-2.22)

0.004

CCP-2−Multiplex−

183 (79)

54 (21)

Reference

 

CCP-2−Multiplex+

90 (79)

24 (21)

0.90 (0.53-1.56)

0.71

CCP-2−Multiplex+

90 (79)

24 (21)

Reference

 

CCP-2+Multiplex+

281 (71)

125 (29)

1.67 (1.01-2.74)

0.004

  1. Statistical comparison of the frequency of smokers and HLA-SE alleles in anti-CCP-2-positive versus anti-CCP-2-negative RA patients and within multiplex-positive RA patients
  2. CCP cyclic citrullinated peptide, RA rheumatoid arthritis, OR odds ratio, CI confidence interval